Incyte Corp (NASDAQ: INCY)’s stock price has plunge by -10.74relation to previous closing price of 67.86. Nevertheless, the company has seen a -14.85% plunge in its stock price over the last five trading sessions. barrons.com reported 2025-03-17 that The biopharmaceutical company announces positive results from two skin disease treatment studies. But Wall Street doesn’t think it was enough.
Is It Worth Investing in Incyte Corp (NASDAQ: INCY) Right Now?
The price-to-earnings ratio for Incyte Corp (NASDAQ: INCY) is above average at 223.34x, Company’s 36-month beta value is 0.85.Analysts have differing opinions on the stock, with 10 analysts rating it as a “buy,” 1 as “overweight,” 15 as “hold,” and 0 as “sell.”
The public float for INCY is 190.72M, and currently, short sellers hold a 3.07% ratio of that floaft. The average trading volume of INCY on March 17, 2025 was 1.67M shares.
INCY’s Market Performance
INCY stock saw a decrease of -14.85% in the past week, with a monthly decline of -13.48% and a quarterly a decrease of -16.44%. The volatility ratio for the week is 3.18%, and the volatility levels for the last 30 days are 3.14% for Incyte Corp (INCY). The simple moving average for the past 20 days is -13.96% for INCY’s stock, with a -10.55% simple moving average for the past 200 days.
Analysts’ Opinion of INCY
Many brokerage firms have already submitted their reports for INCY stocks, with UBS repeating the rating for INCY by listing it as a “Neutral.” The predicted price for INCY in the upcoming period, according to UBS is $77 based on the research report published on December 17, 2024 of the previous year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see INCY reach a price target of $90, previously predicting the price at $68. The rating they have provided for INCY stocks is “Buy” according to the report published on October 29th, 2024.
Wolfe Research gave a rating of “Outperform” to INCY, setting the target price at $84 in the report published on October 01st of the previous year.
INCY Trading at -15.21% from the 50-Day Moving Average
After a stumble in the market that brought INCY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.85% of loss for the given period.
Volatility was left at 3.14%, however, over the last 30 days, the volatility rate increased by 3.18%, as shares sank -13.63% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.94% lower at present.
During the last 5 trading sessions, INCY fell by -14.49%, which changed the moving average for the period of 200-days by +6.24% in comparison to the 20-day moving average, which settled at $70.41. In addition, Incyte Corp saw -12.31% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at INCY starting from BARRY FLANNELLY, who proposed sale 19,807 shares at the price of $67.69 back on Mar 14 ’25. After this action, BARRY FLANNELLY now owns shares of Incyte Corp, valued at $1,340,728 using the latest closing price.
Denton Sheila A., the EVP & General Counsel of Incyte Corp, sale 599 shares at $69.99 during a trade that took place back on Mar 04 ’25, which means that Denton Sheila A. is holding 25,848 shares at $41,924 based on the most recent closing price.
Stock Fundamentals for INCY
Current profitability levels for the company are sitting at:
- 0.01 for the present operating margin
- 0.92 for the gross margin
The net margin for Incyte Corp stands at 0.01. The total capital return value is set at 0.02. Equity return is now at value 0.76, with 0.53 for asset returns.
Based on Incyte Corp (INCY), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at 7.7. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is 27.31.
Currently, EBITDA for the company is 408.16 million with net debt to EBITDA at -6.23. When we switch over and look at the enterprise to sales, we see a ratio of 2.39. The receivables turnover for the company is 4.97for trailing twelve months and the total asset turnover is 0.78. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.97.
Conclusion
In a nutshell, Incyte Corp (INCY) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
